journal
MENU ▼
Read by QxMD icon Read
search

Breast Care

journal
https://www.readbyqxmd.com/read/30319333/news-from-asco-2018
#1
Marija Balic, Natalija Dedic, Leticia De Mattos-Arruda, Simon Gampenrieder
No abstract text is available yet for this article.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319332/primary-rhabdomyosarcoma-of-the-breast-imaging-findings-and-literature-review
#2
Zuhal Bayramoglu, Rejin Kebudi, Ravza Yilmaz, Sema Buyukkapu Bay, Abut Kebudi, Hasan Karanlik, Ayca Iribas, Emin Darendeliler, Semen Onder, Bilge Bilgic, Ibrahim Adaletli
Background: Primary breast rhabdomyosarcoma (RMS) can occur in children. There is a lack of knowledge regarding radiologic findings and added diffusion-weighted magnetic resonance imaging (MRI) features of RMS in the literature. Case Report: A 12-year-old girl was diagnosed with primary alveolar RMS of the breast. Gray scale ultrasound revealed posterior acoustic enhancement behind a well-circumscribed, multilobulated hypoechoic mass. Doppler ultrasound revealed increased peripheral and central vascularity...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319331/recent-developments-in-radiation-oncology-an-overview-of-individualised-treatment-strategies-in-breast-cancer
#3
REVIEW
Montserrat Pazos, Stephan Schönecker, Daniel Reitz, Paul Rogowski, Maximilian Niyazi, Filippo Alongi, Christiane Matuschek, Michael Braun, Nadia Harbeck, Claus Belka, Stefanie Corradini
Radiation therapy (RT) for breast cancer has dramatically changed over the past years, leading to individualized risk-adapted treatment strategies. Historically, the choice of RT regimen was limited to conventional fractionation protocols using standard tangential fields. Nowadays, technological and technical improvements in modern RT have added a variety of other RT modalities, different fractionation schedules, and individualised treatment volumes to the portfolio of breast RT. This review aims to give a short overview on the main topics which have recently found their way into clinical practice: hypofractionated treatment protocols, accelerated partial breast irradiation (APBI) for low-risk patients, deep inspiration breath hold (DIBH) for maximal heart protection, extent of regional nodal irradiation for high-risk patients, and the implementation of new radiation techniques such as intensity modulated RT (IMRT) and volumetric modulated RT (VMAT)...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319330/late-administration-of-trastuzumab-emtansine-might-lead-to-loss-of-chance-for-better-outcome-in-patients-with-her2-positive-metastatic-breast-cancer
#4
REVIEW
Luis Manso, Alfonso Sanchez-Muñoz, Isabel Calvo, Yann Izarzugaza, Jessica Plata, Cesar Rodriguez
The optimal sequence of anti-human epidermal growth factor receptor 2 (HER2) therapies in metastatic breast cancer (MBC) is still undetermined. Physicians must therefore make decisions based on clinical trials and their own experience for the best treatment sequence in these patients. The objective of this review is to summarize the efficacy and safety data for trastuzumab emtansine (T-DM1) in patients with MBC. Additionally, the concept of 'loss of chance for a better outcome' is investigated. It applies to patients who are not receiving the best possible treatment for their disease...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319329/explorative-analysis-of-low-dose-metronomic-chemotherapy-with-cyclophosphamide-and-methotrexate-in-a-cohort-of-metastatic-breast-cancer-patients
#5
Slavomir Krajnak, Marco Battista, Walburgis Brenner, Katrin Almstedt, Tania Elger, Anne-Sophie Heimes, Annette Hasenburg, Marcus Schmidt
Background: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined the therapeutic effects and side effects of LDMC in a cohort of MBC patients. Methods: Patients with MBC were included when LDMC with oral cyclophosphamide (CTX) and methotrexate (MTX) was administered between 2009 and 2015. The primary endpoint was disease control rate (DCR) ≥ 24 weeks after the start of LDMC...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319328/prevalence-of-cardiac-disease-in-breast-cancer-patients-at-time-of-diagnosis-compared-to-the-general-female-population-in-germany
#6
Eva Lorenz, Maria Blettner, Björn Lange, Marcus Schmidt, Astrid Schneider, Lukas Schwentner, Daniel Wollschläger, Hiltrud Merzenich
Background: Advances in oncological therapy have significantly improved breast cancer survival; therefore comorbid conditions are becoming more relevant. We investigated the prevalence of prior cardiovascular diseases and risk factors in patients with breast cancer compared to those in the general female population in Germany. Methods: The PASSOS heart study is a retrospective multicenter cohort study on cardiac late effects in breast cancer patients treated between 1998 and 2008...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319327/neoadjuvant-model-as-a-platform-for-research-in-breast-cancer-and-novel-targets-under-development-in-this-field
#7
REVIEW
Santiago Escrivá-de-Romaní, Miriam Arumí, Esther Zamora, Meritxell Bellet
For decades, the neoadjuvant setting has provided a useful scenario for research in breast cancer. Historically, neoadjuvant clinical trials, either hormone therapy-based or chemotherapy-based, have tried to recapitulate the results of their counterpart adjuvant studies, but with smaller patient numbers, more rapid outcomes (clinical response and/or pathologic complete response (pCR)), together with additional biologic information. As for neoadjuvant chemotherapy trials, the increase in pCR rates has been recently accepted as an appropriate surrogate marker to accelerate drug approval in high-risk breast cancer patients...
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319326/standard-neoadjuvant-treatment-in-early-locally-advanced-breast-cancer
#8
REVIEW
Cristina Pernaut, Flora Lopez, Eva Ciruelos
Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy in luminal tumors, double blockade in HER2-positive tumors, and the use of platinum salts in triple-negative tumors.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319325/surgical-management-of-breast-cancer-treated-with-neoadjuvant-therapy
#9
REVIEW
Octavi Cordoba, Lourdes Carrillo-Guivernau, Carmen Reyero-Fernández
Neoadjuvant therapy (NAT) allows downstaging in some cases of breast cancer. By consequence, it may enable a more conservative surgical approach or make surgery possible in cases ineligible for surgery before NAT. In this article, we review the evidence and management recommendations for optimal surgical treatment in this setting.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30319324/from-standard-of-care-to-the-neoadjuvant-model-as-an-innovative-platform-for-exploring-promising-combinations-in-breast-cancer
#10
EDITORIAL
Cristina Saura
No abstract text is available yet for this article.
August 2018: Breast Care
https://www.readbyqxmd.com/read/30069183/parp-inhibitors-in-breast-cancer-why-how-and-when
#11
Angelo Paradiso, Eleni Andreopoulou, Pierfranco Conte, Alexandru Eniu, Mahasti Saghatchian
No abstract text is available yet for this article.
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069182/ago-recommendations-for-the-diagnosis-and-treatment-of-patients-with-advanced-and-metastatic-breast-cancer-update-2018
#12
Cornelia Liedtke, Christian Jackisch, Marc Thill, Christoph Thomssen, Volkmar Müller, Wolfgang Janni
No abstract text is available yet for this article.
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069181/ago-recommendations-for-the-diagnosis-and-treatment-of-patients-with-early-breast-cancer-update-2018
#13
Cornelia Liedtke, Christian Jackisch, Marc Thill, Christoph Thomssen, Volkmar Müller, Wolfgang Janni
No abstract text is available yet for this article.
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069180/a-case-report-of-triple-positive-micropapillary-carcinoma-of-the-male-breast
#14
Jamila Shuja, Iftikhar Ahmad, Sidra Arshad, Hina Manzoor, Shahwali Kakar, Khushnaseeb Ahmad
Background: Micropapillary carcinoma (MPC), a morphologically distinct subtype of invasive ductal carcinoma, of the male breast is an exceedingly uncommon disease. Case Report: Herein, we report a case of triple-positive MPC of the male breast with axillary lymph node involvement and no recurrence for over 2 years. Specifically, a 60-year-old male patient presented with a hard, elastic, and well-defined painless mass in the right breast. The patient underwent unilateral (right) modified radical mastectomy with axillary clearance...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069179/effects-of-music-intervention-on-the-physical-and-mental-status-of-patients-with-breast-cancer-a-systematic-review-and-meta-analysis
#15
REVIEW
Xia Wang, Yin Zhang, Yao Fan, Xiang-Sheng Tan, Xun Lei
Background: The aim of this review was to evaluate the effects of music intervention on the physical and mental status of patients with breast cancer. Methods: 9 databases were searched; 30 randomized controlled trials that compared the effects of music plus standard care and standard care alone in patients with breast cancer were included. Methodological quality was assessed using the Jadad scale. Results: The results of the meta-analysis suggested that music intervention was significantly effective in lowering systolic blood pressure (standardized mean difference (SMD) -0...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069178/metronomic-chemotherapy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer-a-phase-ii-trial
#16
Emilia Montagna, Vincenzo Bagnardi, Giuseppe Cancello, Claudia Sangalli, Eleonora Pagan, Monica Iorfida, Manuelita Mazza, Giovanni Mazzarol, Silvia Dellapasqua, Elisabetta Munzone, Aaron Goldhirsch, Marco Colleoni
Background: Few data are available on the benefit of metronomic cyclophosphamide, capecitabine, and vinorelbine as first-line therapy in patients with metastatic triple-negative breast cancer. Methods: This phase II study assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine 40 mg orally 3 times a week, cyclophosphamide 50 mg daily, and capecitabine 500 mg 3 times a day (VEX regimen) in untreated metastatic triple-negative breast cancer patients...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069177/lymph-node-radiotherapy-instead-of-extended-axillary-surgery-the-new-standard
#17
REVIEW
Peter Niehoff, Silla Hey-Koch
Breast cancer treatment has undergone major changes in the last 20 years. Specifically, the role of axillary lymph node dissection has changed from radical axillary dissection with excision of a high number of lymph nodes to sentinel lymph node biopsy (SLNB). This paradigm shift is associated with a controversial debate regarding the significance of axillary staging, the need for surgery, and the role of radiotherapy. Looking ahead, lymph node staging and axillary treatment might shift from SLNB and/or axillary dissection to ultrasound-guided needle biopsy and irradiation of regional lymph nodes in order to reduce treatment-related sequelae in early-stage breast cancer...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069176/proton-therapy-for-primary-breast-cancer
#18
REVIEW
Eugen B Hug
Proton therapy reduces the integral dose received by normal tissues due to its physical properties of dose deposition in the Bragg peak. In a small but significant percentage of patients requiring adjuvant radiotherapy (RT) for left-sided breast cancer, photon-based RT can lead to cardiac complications during long-term follow-up. The risk of cardiac complications is correlated with the dose to the coronary arteries and to the general 'mean heart dose'. Dosimetric comparison analysis has identified advantages of proton therapy in accomplishing sparing of the heart with increasing target complexity while permitting uncompromised target coverage of the chest wall ± breast plus draining lymphatics...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069175/intraoperative-electron-radiotherapy-ioert-in-the-treatment-of-primary-breast-cancer
#19
REVIEW
Julia Kaiser, Roland Reitsamer, Peter Kopp, Christoph Gaisberger, Michael Kopp, Thorsten Fischer, Franz Zehentmayr, Felix Sedlmayer, Gerd Fastner
IOERT (intraoperative electron radiotherapy) in breast cancer is used either as a boost (10-12 Gy) followed by whole breast irradiation (WBI) or as full-dose partial breast irradiation (PBI, 20-24 Gy) during breast-conserving surgery. IOERT has the longest evidence of all IORT techniques. When administered as a boost, excellent low local recurrence rates were observed in long-term follow-up >5 years. Even in high-risk groups like triple-negative or locally advanced breast cancers, IOERT contributes to long-term local control rates of more than 90%...
July 2018: Breast Care
https://www.readbyqxmd.com/read/30069174/the-role-of-brachytherapy-in-the-treatment-of-breast-cancer
#20
REVIEW
Daniela Kauer-Dorner, Daniel Berger
Radiotherapy plays an important part in the management of breast cancer. Especially after breast-conserving surgery, external whole breast irradiation, occasionally with an additional local boost, is an integral part of breast conservation. Besides external radiation techniques, brachytherapy (BT) has long been among the treatment options, especially with regard to local boost application. With the emerging implementation of accelerated partial breast irradiation (APBI), BT in general and interstitial multi-catheter BT in particular, are gaining an increasing role in the management of a selected group of early breast cancer patients...
July 2018: Breast Care
journal
journal
41130
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"